The protein kinase C inhibitor ruboxistaurin [LY 333531] improves symptomatic diabetic peripheral neuropathy, according to results from a phase II study presented at the 62nd Scientific Sessions of the American Diabetes Association (ADA) [San Francisco, US; June 2002]. Nerve function and sensory symptoms were significantly improved in ruboxistaurin recipients in this placebo-controlled study.'We are very encouraged to see important early results for LY 333531 in diabetic peripheral neuropathy after only one year',said Dr Skip Vignati, medical director for protein kinase C inhibitor research at Eli Lilly.